APA

Green C., Linch D. C. & Gale R. E. (20090519). Most acute myeloid leukaemia patients with intermediate mutant FLT3/ITD levels do not have detectable bi-allelic disease, indicating that heterozygous disease alone is associated with an adverse outcome. : British journal of haematology.

Chicago

Green Claire, Linch David C and Gale Rosemary E. 20090519. Most acute myeloid leukaemia patients with intermediate mutant FLT3/ITD levels do not have detectable bi-allelic disease, indicating that heterozygous disease alone is associated with an adverse outcome. : British journal of haematology.

Harvard

Green C., Linch D. C. and Gale R. E. (20090519). Most acute myeloid leukaemia patients with intermediate mutant FLT3/ITD levels do not have detectable bi-allelic disease, indicating that heterozygous disease alone is associated with an adverse outcome. : British journal of haematology.

MLA

Green Claire, Linch David C and Gale Rosemary E. Most acute myeloid leukaemia patients with intermediate mutant FLT3/ITD levels do not have detectable bi-allelic disease, indicating that heterozygous disease alone is associated with an adverse outcome. : British journal of haematology. 20090519.